RAVINDER KAUR: Open Payments
NPI 1952936346 · LIVINGSTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$460 in 20 payments from 12 companies in 2025. Trend: 2023 $83 · 2024 $122 · 2025 $460
Food & beverage: $460
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $94 |
| Novartis Pharmaceuticals Corporation | 3 | $62 |
| Lilly USA, LLC | 2 | $60 |
| Amgen Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| Lundbeck LLC | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
Products named: REXULTI, JARDIANCE, LEQVIO, MOUNJARO, EVENITY, CAPLYTA, OFEV, TRELEGY ELLIPTA.
Industry payments across CA — which companies pay providers there.
